Cytisinicline

The comparator was placebo rather than another cessation medication. The primary endpoint assessed abstinence near the end of treatment; follow-up extended to week 24. The trial therefore does not establish comparative effectiveness against active medication or durability beyond 24 weeks.

The study replicated placebo-controlled findings but did not compare cytisinicline with an active cessation medication. Of 792 randomized participants, 628 completed the trial. Follow-up through week 24 does not establish longer-term abstinence or safety.

This open-label study had no concurrent comparator. It enrolled participants previously treated in the ORCA program, rather than a newly recruited randomized population. Exposure declined from 475 treated participants to 281 with at least 51 weeks of treatment. The exit survey was voluntary.

The primary endpoint measured cigarette reduction, not sustained smoking cessation. The table’s four-week abstinence label refers to seven-day point-prevalence abstinence at the end of treatment, not four weeks of continuous abstinence. Continuous abstinence was evaluated separately during weeks 5–8.

This study enrolled adults who vaped but did not currently smoke cigarettes. It therefore provides supporting evidence for vaping cessation rather than a direct estimate of smoking-cessation efficacy. The investigators called for a larger trial with longer follow-up.

This was a single-center trial with minimal counseling and a 25-day cytisine regimen. Its results do not directly test the 6-week or 12-week, 3 mg three-times-daily regimen evaluated in ORCA-2.

Treatment was open-label and the primary outcome was self-reported abstinence at one month. Cytisine and nicotine replacement therapy were given for different durations. These features limit blinding and comparability with trials using biochemical verification as the primary outcome.

Enrollment was 679 participants compared with a planned 2,140. The open-label design and recruitment below target limit precision and leave potential reporting and performance bias. The population and 12-week cytisine regimen differ from other historical cytisine trials.

The primary analysis did not establish noninferiority. Cytisine was administered for 25 days and varenicline for 84 days, so the comparison combines differences in medication and duration. The trial was open-label.

The study population had pulmonary tuberculosis, and both groups received brief behavioral support. The investigators did not support adding cytisine in this setting. Results should not be treated as a direct evaluation of the ORCA regimen in the general smoking population.

This single-center trial enrolled current heavy smokers in lung-cancer screening. Its control was counseling alone rather than placebo tablets or an active cessation medication. Applicability to other smoking populations and comparative tolerability against active medication remain uncertain.

The trial included 67 participants receiving cytisine and 65 receiving placebo. The week-48 relative-risk confidence interval included no difference (relative risk 2.41; 95% confidence interval 0.80–7.35; P = 0.102). The small groups limit precision and assessment of uncommon harms.

The observed relative-risk confidence interval, 0.91–1.81, includes no difference. The nonsignificant comparison does not by itself establish equivalence. Cytisine and nortriptyline were administered for different durations.

This pilot recruited 13 participants and nine completed follow-up. It was designed to evaluate recruitment and adherence, not to provide a definitive comparative efficacy estimate. Its end-of-treatment cessation findings are therefore exploratory.

The report contains a protocol, not observed cessation or safety results. Planned comparisons are open-label and use 25-, 50-, and 75-day courses. The clinically evaluable analysis population may differ from all randomized participants.

Allocation was not randomized, and there was no placebo group or direct comparison with the standard 25-day cytisine regimen. The observed differences cannot establish that extending treatment to 40 days caused improved outcomes.

The evidence comes from a prospective observational cohort of 36 hospitalized smokers with cardiovascular disease. Its small size and lack of randomized comparison limit causal interpretation and assessment of uncommon cardiovascular harms. The reported longitudinal cessation percentages are self-reported outcomes.

Treatment selection reflected routine practice rather than randomization, and multivariable modeling was not performed. The association between adherence and cessation does not establish a causal medication effect or an adjusted comparative treatment effect.

Abstinence was self-reported. The study enrolled men working in mining, limiting direct applicability to broader clinical populations. It evaluated a 25-day regimen rather than the longer ORCA regimens.

This is an indirect comparison, not a randomized head-to-head trial. Weighting cannot remove confounding from unmeasured differences between trials. The weeks 9–12 odds-ratio confidence interval includes no difference, while the weeks 9–24 interval does not. These estimates should not be interpreted as head-to-head evidence.

The study characterized a single dose in healthy smokers. It does not establish smoking-cessation efficacy or the safety of repeated administration for 6 or 12 weeks.

The pharmacokinetic study included 10 healthy adult smokers and used the standard 25-day regimen. It provides evidence of accumulation but cannot establish clinical cessation efficacy or detect uncommon harms.